Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06819670 · ClinicalTrials.gov registry record · Phase 2
A Study to Prevent Infantile Spasms Relapse
A Phase 2 study of Infantile Spasms and Infantile Epileptic Spasms Syndrome, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06819670: Recruiting Phase 2 study of Infantile Spasms and Infantile Epileptic Spasms Syndrome, sponsored by University of California, Los Angeles.
NCT06819670 is a Phase 2 study of Infantile Spasms and Infantile Epileptic Spasms Syndrome that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 40 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06819670, a Phase 2 study of Infantile Spasms and Infantile Epileptic Spasms Syndrome, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
After initially successful treatment, many children with infantile spasms unfortunately have a relapse, and relapse is linked to poor long-term outcomes such as autism and other forms of epilepsy. The aim of this study is to determine if treatment with low-dose prednisolone is safe, well tolerated, and effective in reducing the risk of relapse.
Primary Outcome
The investigators will tabulate of adverse events and determine whether any adverse event is associated with prednisolone treatment during the first 5 months of the study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Prednisolone
- DRUG Famotidine
Study Locations (1)
California
- UCLA - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-05-05 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 2 |
What NCT06819670 shows while recruiting
NCT06819670 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower).
The record links to 3 conditions, with Infantile Spasms appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06819670 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06819670 about?
NCT06819670 is a clinical study titled "A Study to Prevent Infantile Spasms Relapse". After initially successful treatment, many children with infantile spasms unfortunately have a relapse, and relapse is linked to poor long-term outcomes such as autism and other forms of epilepsy. The aim of this study is to determine if treatment with low-dose prednisolone is safe, well tolerated, ...
What is the current status of trial NCT06819670?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-05-05. Estimated completion is 2028-06-30.
What conditions does trial NCT06819670 study?
This clinical trial studies the following conditions: Infantile Spasms, Infantile Epileptic Spasms Syndrome, West Syndrome.
What interventions are being tested in trial NCT06819670?
The interventions under investigation include: Placebo (DRUG), Prednisolone (DRUG), Famotidine (DRUG).
Who is sponsoring clinical trial NCT06819670?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06819670 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infantile Spasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06819670's enrollment target sits among peer trials
40 1362nd of 2000 higher than 542 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI